-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 21, Jilin issued the "Spring Ring Medical Consumables Inter-provincial Alliance Centralized Procurement Document (Draft for Comments)", which will soon be led by Jilin to launch the collective procurement
of 21 provincial spring ring alliances.
of 21 provincial spring ring alliances.
Spring ring collection has covered 25 provinces
At present, there is no movement in 7 provinces and cities including Shanghai, Zhejiang and Guangdong
The Pharmaceutical Cloud Studio found that the scope of collective procurement in the Draft for Comments was one less than the scope of the previous centralized procurement information confirmation in August, after all, Hebei had taken the lead in completing the centralized procurement and had already implemented the results
.
.
The provinces to be covered this time include: Heilongjiang, Jilin, Liaoning, Inner Mongolia, Shandong, Shanxi, Henan, Shaanxi, Jiangxi, Hunan, Hubei, Chongqing, Guizhou, Guangxi, Hainan, Ningxia, Gansu, Qinghai, Tibet, Xinjiang and the Xinjiang Corps, totaling 21 provinces, municipalities and regions
.
.
In addition, Anhui Province is also about to carry out collective procurement
.
The "Anhui Province Spring Ring (Intracranial) Medical Consumables Centralized Procurement Document (Draft for Comments)" was also issued by the Anqing Municipal Medical Insurance Bureau of Anhui Province
.
.
The "Anhui Province Spring Ring (Intracranial) Medical Consumables Centralized Procurement Document (Draft for Comments)" was also issued by the Anqing Municipal Medical Insurance Bureau of Anhui Province
.
So far, spring ring centralized procurement has covered or will soon cover 25 provinces, only Beijing, Tianjin, Shanghai, Zhejiang, Guangdong, the five major markets, and Sichuan, Yunnan and other 7 provinces and cities have not issued relevant procurement information
.
.
Hebei, Jiangsu and Fujian have produced collective procurement results, among which the average reduction rate of spring coils in Hebei Province is 46.
82%, the highest reduction rate is 66%, the average reduction rate of Jiangsu is 54%, and the 10 enterprises involved in Fujian are all in the middle
.
The price of spring rings has dropped from tens of thousands to about 3,000 yuan at present
.
82%, the highest reduction rate is 66%, the average reduction rate of Jiangsu is 54%, and the 10 enterprises involved in Fujian are all in the middle
.
The price of spring rings has dropped from tens of thousands to about 3,000 yuan at present
.
The procurement scale and procurement methods of the 21 provinces will attract great attention from the industry, and the procurement ideas will also have a certain impact
on the 7 provinces and cities that have not been purchased in the future on the basis of learning from the experience of Hebei, Jiangsu and Fujian.
on the 7 provinces and cities that have not been purchased in the future on the basis of learning from the experience of Hebei, Jiangsu and Fujian.
The selection rules of the 21 provincial spring ring collective procurement alliance are relatively modest
A resurrection mechanism exists in both groups of AB
From the perspective of the centralized procurement rules of the 21 provinces, the proposed selection rules are quite moderate, and the products are divided into two groups
of AB according to the size of the medical institutions.
of AB according to the size of the medical institutions.
The 2 products in Group A with the highest quotation are eliminated, and the others are planned to be selected; Moreover, the "eliminated" two companies also have a resurrection mechanism, as long as the quotation is not higher than 1.
8 times the lowest price of the proposed selection, they can also be eligible
for the proposed selection.
8 times the lowest price of the proposed selection, they can also be eligible
for the proposed selection.
Group B will first eliminate the registration certificates with the highest 50% of the quotation, and likewise, there is a resurrection mechanism for these "eliminated" products, and they can also be eligible
if their quotation is not higher than 0.
8 times the average price of the proposed selection in Group A.
if their quotation is not higher than 0.
8 times the average price of the proposed selection in Group A.
In addition, it should be noted that there are also provisions for the prices of the two groups A/B: the price to be selected in group B needs to be ≤ the highest proposed price in group A
.
to achieve price balance between
the two groups.
.
to achieve price balance between
the two groups.
The next step is to look at the amount reported by the medical institution and the maximum effective declaration price
From Hebei, Jiangsu to Fujian, the idea of spring ring collection and mining has been continuously optimized
.
From the perspective of procurement volume, the procurement demand of the three provinces is:
.
From the perspective of procurement volume, the procurement demand of the three provinces is:
Hebei: 13,132 (70% of the reported volume)
Jiangsu: 28,163 (80% of purchases by platform)
Fujian: 7,225 (let the manufacturer first declare the information, and then let the medical institution report the amount based on the information)
Jiangsu's procurement volume is more than twice that of Hebei and nearly 4 times
that of Fujian.
that of Fujian.
The consultation draft does not publish the information reported by medical institutions and the highest effective declaration price, both of which are very important references for manufacturers, after all, the volume and price of centralized procurement are linked, and enterprises will be willing to follow up
when they see that there is enough volume.
when they see that there is enough volume.
The localization rate is less than 10%, but there is no restricted area for collective procurement
The coil coil is currently one of the main minimally invasive interventional devices for the treatment of
intracranial aneurysm.
The spring ring is often connected with a metal push rod, which is pushed into the cavity through the catheter, and then the spring ring mechanical occlusion effect and secondary thromboocclusive effect are used to isolate the aneurysm from the blood circulation of the aneurysm artery to achieve the purpose
of preventing aneurysm rupture.
intracranial aneurysm.
The spring ring is often connected with a metal push rod, which is pushed into the cavity through the catheter, and then the spring ring mechanical occlusion effect and secondary thromboocclusive effect are used to isolate the aneurysm from the blood circulation of the aneurysm artery to achieve the purpose
of preventing aneurysm rupture.
According to the analysis of "OneHub Medical", neurointervention, peripheral intervention and electrophysiological products have always been recognized as the "blue ocean" market for many enterprises due to large market
demand, low domestic substitution rate and relatively few competitors.
demand, low domestic substitution rate and relatively few competitors.
Taking embolic spring rings as an example, in 2018, Medtronic, MicroVention, Johnson & Johnson, and Stryker alone occupied more than 90% of the market share of China's spring coil market, and only 6%
were domestically produced.
were domestically produced.
After the collection of coronary stents, many coronary stent manufacturers began to turn to neurointerventional products
.
As of June 2021, at least 24 innovative enterprises in China have developed and deployed neurointerventional products
.
From 2020 to June 2021, the number of investment and financing events in the field of neurointerventional exceeded 15, with a cumulative financing amount of more than 1.
5 billion RMB
.
According to the statistics of Arterial Network, as of December 2, 2021, at least 22 neurointerventional products have been approved
in China.
.
As of June 2021, at least 24 innovative enterprises in China have developed and deployed neurointerventional products
.
From 2020 to June 2021, the number of investment and financing events in the field of neurointerventional exceeded 15, with a cumulative financing amount of more than 1.
5 billion RMB
.
According to the statistics of Arterial Network, as of December 2, 2021, at least 22 neurointerventional products have been approved
in China.
According to relevant information, at present, at least 24 innovative enterprises and 60 investment institutions in the field of neurointerventional in China have betted
.
With the continuous development of minimally invasive surgery and the support of national policies, neurointerventional medical devices still have a lot of room for
development.
According to the Prospective Industry Research Institute, it is estimated that by 2030, China's neurointerventional device market will reach 48.
8 billion yuan
.
.
With the continuous development of minimally invasive surgery and the support of national policies, neurointerventional medical devices still have a lot of room for
development.
According to the Prospective Industry Research Institute, it is estimated that by 2030, China's neurointerventional device market will reach 48.
8 billion yuan
.
The prospect of the industry is considerable, but the trend of price reduction in centralized procurement is irreversible
.
For related enterprises, collective procurement is both an opportunity and a challenge
.
New product research and development, as well as how to expand market share and influence in the competition of existing imported brands and similar domestic new products after the new product is launched, are all issues
that need to be considered urgently.
.
For related enterprises, collective procurement is both an opportunity and a challenge
.
New product research and development, as well as how to expand market share and influence in the competition of existing imported brands and similar domestic new products after the new product is launched, are all issues
that need to be considered urgently.
